Short answer
RHYTHM PHARMACEUTICALS, INC. (RYTM) filed its Q3 2025 10-Q quarterly report on Nov 4, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $51M (up 54.3% year over year) with net income of −$53M.
Q3 2025 key financials · XBRL
- Revenue
- $51M
- +54.3% YoY · +5.8% QoQ
- Net income
- −$53M
- −21.1% YoY · −13.4% QoQ
- Operating margin
- -102.6%
- EPS (diluted)
- −$0.82
- −12.3% YoY · −9.3% QoQ
Source: XBRL data from the RHYTHM PHARMACEUTICALS, INC. (RYTM) Q3 2025 10-Q on SEC EDGAR. USD.
RHYTHM PHARMACEUTICALS, INC. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New risk from July 2025 $188.7M follow-on public offering; impact on capital structure and dilution risk increased
- RIFA royalty burden update: tiered royalties 11.5%-2.5% on net revenues up to $300M+, $34.9M paid through Sept 2025, limits cash flow flexibility
- Regulatory risk: uncertain approvals for setmelanotide indications with Phase 3 EMANATE trial sub-studies and FDA/EMA acceptance variability
- Operational risk: early commercialization stage for IMCIVREE in US, Canada, EU, UK; manufacturing scale-up and market acceptance remain uncertain
- Financial risk: cash/resources $416.1M Sept 2025; prior $100M RIFA debt plus Convertible Preferred Stock $147.8M; risk of capital raising under challenging markets
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other RHYTHM PHARMACEUTICALS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.